Loading
A placeholder for the United Kingdom-specific gaps: where the Targeted Lung Health Check programme has reached and who it misses, how long the pathway takes from scan to treatment, how fast a tumour is genotyped, and which of the drugs on this roadmap are funded.
This record exists so the roadmap can point at the United Kingdom delivery gaps without duplicating them. Programme coverage and uptake by deprivation, the diagnostic interval from abnormal scan to treatment decision, thoracic surgery and radiotherapy capacity, genomic laboratory hub turnaround, which alterations the national test directory covers, and the NICE and Cancer Drugs Fund status of osimertinib, alectinib, lorlatinib, sotorasib, durvalumab and tarlatamab all belong to the UK and NHS page for lung cancer, which owns those numbers.
When the UK page names its gaps, this record takes their titles and its hypothesis and test are rewritten from them. Until then it holds the link between the evidence roadmap and the delivery question, and carries no figures of its own.
The document that defines who is offered a scan in the United States, and therefore the document any argument about the screening eligibility gap has to engage with. Eligibility is still defined by pack-years and years since quitting rather than by an individual risk estimate.
The deprivation gradient in lung cancer is not only about who gets the disease. Among people who already have it, and at the same stage, poorer patients are less likely to be offered the treatment that works.
The case for re-biopsy at progression, for treating resistance as a diagnosis rather than an endpoint, and for the idea of a drug holiday. It is also the origin of resistance-directed sequencing: what you give next should depend on what the tumour became.
Shares Take lung screening scanners to supermarket car parks in the poorest areas, Socioeconomic inequalities in lung cancer treatment: systematic review and meta-analysis, Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement, Not enough oncologists, nurses, pathologists, physicists and the tag lung-evidence.
Shares Take lung screening scanners to supermarket car parks in the poorest areas, Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement, Lung cancer roadmap: from Doll and Hill and the naming of tobacco, through the cytotoxic plateau, computed tomography screening, EGFR and ALK, immunotherapy by PD-L1, the perioperative trials and PACIFIC, to DLL3 in small-cell disease and a 2032 registry watch, Fragmented care and guideline gaps and the tag lung-evidence.
Shares Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors, Diagnostics roadmap: stains → gene panels → blood tests that decide treatment, Next-generation sequencing (NGS), Lung cancer roadmap: from Doll and Hill and the naming of tobacco, through the cytotoxic plateau, computed tomography screening, EGFR and ALK, immunotherapy by PD-L1, the perioperative trials and PACIFIC, to DLL3 in small-cell disease and a 2032 registry watch and the tag lung-evidence.
Shares Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement, Lung cancer roadmap: from Doll and Hill and the naming of tobacco, through the cytotoxic plateau, computed tomography screening, EGFR and ALK, immunotherapy by PD-L1, the perioperative trials and PACIFIC, to DLL3 in small-cell disease and a 2032 registry watch, The hardest cancers are found late, Most of the world has almost no cancer care and the tag lung-evidence.
Shares Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement, Lung cancer roadmap: from Doll and Hill and the naming of tobacco, through the cytotoxic plateau, computed tomography screening, EGFR and ALK, immunotherapy by PD-L1, the perioperative trials and PACIFIC, to DLL3 in small-cell disease and a 2032 registry watch, The hardest cancers are found late, Liquid biopsy (ctDNA) and the tag lung-evidence.
Shares Next-generation sequencing (NGS), Lung cancer roadmap: from Doll and Hill and the naming of tobacco, through the cytotoxic plateau, computed tomography screening, EGFR and ALK, immunotherapy by PD-L1, the perioperative trials and PACIFIC, to DLL3 in small-cell disease and a 2032 registry watch, The hardest cancers are found late, Liquid biopsy (ctDNA) and the tag lung-evidence.
Shares Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors, Next-generation sequencing (NGS), Lung cancer roadmap: from Doll and Hill and the naming of tobacco, through the cytotoxic plateau, computed tomography screening, EGFR and ALK, immunotherapy by PD-L1, the perioperative trials and PACIFIC, to DLL3 in small-cell disease and a 2032 registry watch, Lung cancer (all types) and the tag lung-evidence.
Shares Lung cancer roadmap: from Doll and Hill and the naming of tobacco, through the cytotoxic plateau, computed tomography screening, EGFR and ALK, immunotherapy by PD-L1, the perioperative trials and PACIFIC, to DLL3 in small-cell disease and a 2032 registry watch, The hardest cancers are found late, Lung cancer (all types), Non-small-cell lung cancer and the tag lung-evidence.